The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2023 | The importance of evaluating qualitative outcomes of patients with CLL on targeted therapy
Dima El-Sharkawi, MBBS, MA, PhD, MRCP, FRCPath, The Royal Marsden NHS Foundation Trust, Sutton, UK, comments on the importance of evaluating targeted therapies for the treatment of chronic lymphocytic leukemia (CLL) from the patient perspective. Dr El-Sharkawi explains that most clinical trials focus on primary and secondary endpoints from the medical perspective, however, very few studies consider how these agents will affect patients’ lives on a daily basis. Dr El-Sharkawi emphasizes that gathering this qualitative data will be important to improve patients’ understanding of their treatment. This interview took place at the 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) 2023, held in Birmingham, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria: Abbvie; AstraZeneca; Beigene; Gilead, Janssen; Lily; Roche; Takeda
Conference/ Travel support: Abbvie; Novartis; Roche
Ad boards: Abbvie; ASTEX; AstraZeneca; Beigene; Janssen; Kyowa Kiirin
